News | January 30, 2026
Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The newly certified kits are designed for early detection and large-scale screening programs
The collaboration will center on expanding access to Eastman’s Esmeri technology
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
Subscribe To Our Newsletter & Stay Updated
